The Centers for Medicare and Medicaid Services (CMS) Deadline: October 1st Companies must agree to negotiate pricing with the federal government or face penalties.
Those who decide not to negotiate have two choices: a heavy consumption tax; withdraw all products Some have already said they intend to sign the agreement, even though they have filed lawsuits to block it from Medicare and Medicaid coverage.
“We believe that patients can use FARXIGA plan to participate “In the process outlined by CMS to communicate the value of FARXIGA to Medicare recipients,” an AstraZeneca spokesperson said.
Merck & Co. announces signing of agreement “Protesting.”
“If we withdraw all of their products from Medicare and Medicaid, catastrophic consequences “For millions of Americans who rely on our innovative medicines, it is unacceptable for any manufacturer to relinquish nearly half of the U.S. prescription drug market,” Merck said.
A Bristol-Myers Squibb spokesperson similarly said the company had “no choice but to sign the ‘contract’.”
AstraZeneca’s diabetes drug FasigaMerck & Co.’s type 2 diabetes treatment Janubia and Bristol-Myers Squibbs Eliquis They were among the first 10 drugs selected by the Biden administration last month.
Others were more fuzzy About their plans.
When asked about its intentions, Novo Nordisk said: “To drive change for those who need it, continue to bring innovative medicines to market and increase access to medicines for those who need them. We will continue to consider all possible options.”
There was a possibility that the two companies could have avoided further negotiations, but a federal judge’s ruling on Friday dashed those hopes.
The Chamber of Commerce is one of many groups suing to stop the program. preliminary injunction Complete the procedure by October 1st.
But U.S. District Judge Michael J. Newman found in Friday’s ruling that the organization had failed to prove it needed an injunction.
“They have not demonstrated that there is a high probability of success or that they will cause irreparable harm. “The request for relief was denied,” Newman wrote.
If the ruling goes into effect, the Medicare negotiation program can proceed as planned.
